Initiate Phase 3 trials of ULTOMIRIS in HSCT-TMA

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 30 Jan 2020
Due: 31 Dec 2020
Delivered: December 2020

Deadline
Met
Late
Not met
Today

What the company said

“followed by Phase 3 trials in the second half of 2020, pending regulatory feedback.”

SourceAlexion Pharmaceuticals Form 8-K press release, 2020-01-30
FilingSEC filing index
Deadline as statedin the second half of 2020
Deadline used31 Dec 2020, the last day of the stated period
TypeProject
Permanent referenceKI-C-2020-C899866-019367
Cite as https://keptindex.org/c/KI-C-2020-C899866-019367/ — this address never changes.

What we found

Evidence strength A What the grades mean

Alexion initiated a Phase III study of ULTOMIRIS (ALXN1210) in HSCT-TMA in December 2020, meeting the commitment to initiate the trial in the second half of 2020.

A
Alexion Pharmaceuticals 10-K filed 2021-02-08 Regulatory filing · published 8 Feb 2021 · retrieved 21 Oct 2026 · kept permanently by the SEC · fingerprint 10caf5605550
“In December 2020, Alexion initiated a Phase III, multicenter study to evaluate the safety and efficacy of ALXN1210 in HSCT-TMA.” ✓ confirmed on the page

Checked 21 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

3 versions

Version 1 · original · stated 30 Jan 2020

Deadline 31 Dec 2020 (“in the second half of 2020”)
Version 2 · stated 30 Jul 2020

Deadline 31 Dec 2021 (“in 2021”)

“followed by Phase 3 trials in 2021, pending regulatory feedback.”
Source for this version
Version 3 · stated 29 Oct 2020

Deadline 31 Dec 2020 (“by the end of 2020”) · wording expected

“Alexion has initiated a Phase 3 study of ULTOMIRIS in adults with HSCT-TMA and plans to initiate a Phase 3 study in children with HSCT-TMA by the end of 2020.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Initiate
Deliverable: Phase 3 trials of ULTOMIRIS in HSCT-TMA
In the company’s control: Medium
Specificity: High
Conditional: Yes: pending regulatory feedback
Depends on: Regulatory

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Alexion Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.